



**Supplementary U.S. Dollar Financial Information
For the six months ended 31 December 2004**

Ansell Limited and its Controlled Entities

ACN 004 085 330

The following unaudited US dollar financial information is supplementary to the Company's Appendix 4D Half Year Report for the six months ended 31 December 2004 filed with the ASX on 9 February 2005. It is provided as additional information for the Company's shareholders. This financial information does not form part of the Company's financial statements that are required to be prepared under the Corporations Act 2001, Australian Accounting Standards and the ASX listing rules.

This financial information has been derived from the Company's Appendix 4D.

Translation of amounts from Australian dollars to US dollars in the Statement of Financial Performance, Statement of Cash Flows and Operating Revenue and Operating Result within the Industry Segments have been made at the average of the 10a.m. mid buy/sell rate for Australian dollars as quoted by Reuters on the last working day of each month for the 7 month period June 2004 to December 2004.

Translation of amounts from Australian dollars to US dollars in the Statement of Financial Position and Assets Employed and Liabilities within the Industry Segments have been made at the 10a.m. mid buy/sell rate for Australian dollars as quoted by Reuters, on Friday 31 December 2004, at US\$0.77835 = A\$1 (30 June 2004 US\$0.68885 = A\$1).

Unaudited U.S. Dollar Financial Information

Statement of Financial Performance

of Ansell Limited and its Controlled Entities for the six months ended 31 December 2004

	2004	2003
	US\$m	US\$m
Revenue		
Sales	395.0	383.4
Other revenue	6.3	4.3
Total revenue	401.3	387.7
Expenses		
Cost of good sold	233.1	227.8
Selling, distribution and administration	102.3	102.1
Depreciation and amortisation	16.9	16.3
Write-down of assets	-	0.7
Total expenses, excluding borrowing costs	352.3	346.9
Borrowing costs	8.6	10.2
Profit from ordinary activities before income tax expense	40.4	30.6
Income tax expense attributable to ordinary activities	8.2	6.3
Net profit from ordinary activities after income tax expense	32.2	24.3
Outside equity interests in net profit after income tax	0.5	0.8
Net profit after income tax attributable to Ansell Limited shareholders	31.7	23.5

	cents	cents
Earnings per share is based on Net Profit/(Loss) after income tax attributable to Ansell Limited shareholders		
Basic earnings per share	18.1	12.7
Diluted earnings per share	18.0	12.6

Unaudited U.S. Dollar Financial Information

Statement of Financial Position

of Ansell Limited and its Controlled Entities

	31 December 2004	30 June 2004
	US\$m	US\$m
Current Assets		
Cash	125.2	212.0
Cash - restricted deposits	6.0	7.1
Receivables ^(b)	161.7	157.5
Inventories	146.7	131.2
Prepayments	13.1	8.1
Total Current Assets	452.7	515.9
Non-Current Assets		
Receivables ^(b)	51.1	43.8
Other investments ^(a)	108.9	97.4
Other property, plant and equipment	155.2	156.9
Intangible assets	196.5	202.1
Tax assets	17.3	16.7
Total Non-Current assets	529.0	516.9
Total Assets	981.7	1,032.8
Current Liabilities		
Payables	108.2	109.8
Interest-bearing liabilities	92.5	131.0
Provisions	43.6	35.8
Current tax liabilities	1.9	1.8
Total Current Liabilities	246.2	278.4
Non-Current Liabilities		
Payables	0.4	2.3
Interest-bearing liabilities	193.5	162.6
Provisions	16.7	16.5
Deferred tax liabilities	15.0	13.9
Total Non-Current Liabilities	225.6	195.3
Total Liabilities	471.8	473.7
Net Assets	509.9	559.1
Equity		
Contributed equity	956.6	953.3
Reserves	(239.2)	(189.9)
Accumulated losses	(214.2)	(211.3)
Total Equity Attributable to Ansell Limited Shareholders	503.2	552.1
Outside equity interests	6.7	7.0
Total Equity	509.9	559.1

(a) Includes investment in South Pacific Tyres Partnership and South Pacific Tyres N.Z. Ltd of US\$ 107.4m (June 2004 US\$ 95.1m).

(b) Includes interest bearing loans to South Pacific Tyres Partnership of US\$ 50.4m (June 2004 US\$ 43.3m).

Unaudited U.S. Dollar Financial Information

Statement of Cash Flows

of Ansell Limited and its Controlled Entities for the six months ended 31 December 2004

	2004 US\$m	2003 US\$m
Cash flows Related to Operating Activities		
Receipts from customers (excluding non recurring and Accufix Research Institute)	395.9	408.6
Payments to suppliers and employees (excluding non recurring and Accufix Research Institute)	(344.0)	(335.9)
Net receipts from customers (excluding non recurring and Accufix Research Institute)	51.9	72.7
Income taxes paid	(3.5)	(6.9)
Net cash provided by operating activities (excluding non recurring and Accufix Research Institute)	48.4	65.8
Non recurring payments to suppliers and employees	-	(3.6)
Payments to suppliers and employees net of customer receipts (Accufix Research Institute)	(1.4)	(1.0)
Net Cash Provided by Operating Activities	47.0	61.2
Cash Flows Related to Investing Activities		
Payments for property, plant and equipment	(5.3)	(3.8)
Proceeds from sale of plant and equipment in the ordinary course of business	-	0.3
Proceeds from sale of other investments	0.6	-
Net Cash Provided by Investing Activities	(4.7)	(3.5)
Cash Flows Related to Financing Activities		
Proceeds from borrowings	46.5	0.6
Repayments of borrowings	(63.3)	(23.3)
Net repayments of borrowings	(16.8)	(22.7)
Proceeds from issues of shares	0.1	0.6
Payments for share buy-back	(120.8)	(25.5)
Dividends paid	(9.1)	(14.1)
Interest received	4.1	2.9
Interest and borrowing costs paid	(9.2)	(10.6)
Net Cash Used in Financing Activities	(151.7)	(69.4)
Net (Decrease)/Increase in Cash Held	(109.4)	(11.7)
Cash at the beginning of the financial period	216.8	198.4
Effects of exchange rate changes on the balances of cash held in foreign currencies at the beginning of the financial period	21.4	14.9
Cash at the End of the Financial Period	128.8	201.6

Unaudited U.S. Dollar Financial Information

Industry Segments

of Ansell Limited and its Controlled Entities for the six months ended 31 December 2004

	Operating Revenue		Operating Result	
	December		December	
	2004 US\$m	2003 US\$m	2004 US\$m	2003 US\$m
INDUSTRY				
Ansell Healthcare				
Occupational Healthcare	198.9	183.1	29.5	22.7
Professional Healthcare	134.2	133.4	15.4	15.0
Consumer Healthcare	61.9	66.9	10.3	12.4
Total Ansell Healthcare	395.0	383.4	55.2	50.1
Unallocated Items	6.3	4.3	(4.3)	(5.4)
Operating EBITA			50.9	44.7
NON RECURRING				
Discontinued Businesses				
Other				5.5
Rationalisation/Restructuring				
Ansell Healthcare				(5.3)
Write-down of assets				
Other				(0.7)
			50.9	44.2
Goodwill amortisation			(7.6)	(7.6)
Earnings before Net Interest and Tax (EBIT)			43.3	36.6
Borrowing Costs net of Interest Revenue			(2.9)	(6.0)
Operating Profit before Tax			40.4	30.6
Tax			(8.2)	(6.3)
Outside Equity Interests			(0.5)	(0.8)
Total Consolidated	401.3	387.7	31.7	23.5
REGIONS				
Asia Pacific	59.2	59.0	14.6	13.8
Americas	199.7	191.8	27.7	21.1
Europe	136.1	132.6	12.9	15.2
	395.0	383.4	55.2	50.1

	Assets Employed		Liabilities	
	December		December	
	2004 US\$m	June 2004 US\$m	2004 US\$m	June 2004 US\$m
INDUSTRY				
Ansell Healthcare				
Occupational Healthcare	210.1	189.3	63.0	66.2
Professional Healthcare	185.6	191.1	46.9	46.9
Consumer Healthcare	73.3	76.0	15.5	25.6
Total Ansell Healthcare	469.0	456.4	125.4	138.7
Unallocated Items	23.0	10.7	331.8	319.6
Discontinued Businesses	162.0	144.5	14.6	15.4
Goodwill and Brand names	196.5	202.1		
Cash	131.2	219.1		
Total Consolidated	981.7	1,032.8	471.8	473.7
REGIONS				
Asia Pacific	183.5	184.8	45.7	51.9
Americas	171.6	156.7	53.1	62.4
Europe	113.9	114.9	26.6	24.4
	469.0	456.4	125.4	138.7

Unaudited U.S. Dollar Financial Information

Notes to the Industry Segments Report

(a) Unallocated Revenue and Costs

Represents costs of Statutory Head Office, part of the costs of Ansell Healthcare's Corporate Head Office and non-sales revenue.

(b) Cash

Cash also includes Accufix Pacing Leads restricted deposits.

(c) Inter-Segment Transactions

Significant inter-segment sales were made by Asia Pacific - US\$74.1 million (2003 - US\$75.1 million) and America - US\$86.3 million (2003 - US\$66.2 million). Inter-segment sales are predominantly made at the same prices as sales to major customers. Operating revenue is shown net of inter-segment values. Accordingly, the Operating revenues shown in each segment reflect only the external sales made by that segment.

(d) Industry Segments

The consolidated entity comprises the following main business segments:

Occupational Healthcare - manufacture and sale of occupational health and safety gloves.

Professional Healthcare - manufacture and sale of medical, surgical and examination gloves for hand barrier protection and infection control.

Consumer Healthcare - manufacture and sale of condoms, household gloves and other personal products.

Discontinued Businesses - represents former Industry Segment businesses which have been sold or abandoned.

(e) Regions

The allocation of Operating Revenue and Operating Results reflect the geographical regions in which the products are sold to external customers. Assets Employed are allocated to the geographical regions in which the assets are located.

Asia Pacific - manufacturing facilities in 4 countries and sales.

Americas - manufacturing facilities in USA and Mexico and significant sales activity.

Europe - principally a sales region with one manufacturing facility in the UK.

	2004 December US\$m	2003 December US\$m
(f) Segment Capital Expenditure		
Occupational Healthcare	2.4	1.2
Professional Healthcare	1.5	1.6
Consumer Healthcare	1.4	1.0
(g) Region Capital Expenditure		
Asia Pacific	2.5	2.5
Americas	2.4	1.0
Europe	0.4	0.3
(h) Segment Depreciation		
Occupational Healthcare	3.3	2.9
Professional Healthcare	4.2	3.9
Consumer Healthcare	1.6	1.9
(i) Segment Other Non Cash Expenses (excluding Provision for Rationalisation and Write-down of Assets separately disclosed)		
Occupational Healthcare	2.8	2.5
Professional Healthcare	0.9	0.4
Consumer Healthcare	0.2	1.3